Akkermansia muciniphila: Difference between revisions
| Line 21: | Line 21: | ||
==Description and Significance== | ==Description and Significance== | ||
[[File:microbewikiakkerman.jpg|200px|thumb|left|Image of ''Akkermansia muciniphila'']] | |||
''Akkermansia muciniphila'' is an anaerobic, Gram-negative, non-motile, non-spore-forming, oval-shaped bacterium.[] It is present in the human intestinal tract in high quantities, ranging from 39% to 84% of the total bacterial population. ''A.muciniphila'' is associated with the protective mucus lining of the intestines. Its presence in the mucus layer of the intestinal tract is particularly important because ''A.muciniphila'' is able to degrade host mucin into short chain fatty acids, or other products, to regulate the biological functions of the host.[] The high content of ''Akkermansia muciniphila'' is thought to play a major role in the health of the intestinal mucos, as well as regulate host immune responses and lipid metabolism. [] Many studies have noticed that a decrease of Akkermansia muciniphila in the mucus is tied with higher rates of obesity, increased inflammation, and an increase in Type 2 diabetes symptoms. [] | ''Akkermansia muciniphila'' is an anaerobic, Gram-negative, non-motile, non-spore-forming, oval-shaped bacterium.[] It is present in the human intestinal tract in high quantities, ranging from 39% to 84% of the total bacterial population. ''A.muciniphila'' is associated with the protective mucus lining of the intestines. Its presence in the mucus layer of the intestinal tract is particularly important because ''A.muciniphila'' is able to degrade host mucin into short chain fatty acids, or other products, to regulate the biological functions of the host.[] The high content of ''Akkermansia muciniphila'' is thought to play a major role in the health of the intestinal mucos, as well as regulate host immune responses and lipid metabolism. [] Many studies have noticed that a decrease of Akkermansia muciniphila in the mucus is tied with higher rates of obesity, increased inflammation, and an increase in Type 2 diabetes symptoms. [] | ||
==Genome Structure== | ==Genome Structure== | ||
Revision as of 02:04, 29 April 2020
Classification
Domain: Bacteria
Phylum: Verrucomicrobia
Class: Verrucomicrobiae
Order: Verrucomicrobiales
Family: Akkermansiaceae
Species
Akkermansia muciniphila
Description and Significance
Akkermansia muciniphila is an anaerobic, Gram-negative, non-motile, non-spore-forming, oval-shaped bacterium.[] It is present in the human intestinal tract in high quantities, ranging from 39% to 84% of the total bacterial population. A.muciniphila is associated with the protective mucus lining of the intestines. Its presence in the mucus layer of the intestinal tract is particularly important because A.muciniphila is able to degrade host mucin into short chain fatty acids, or other products, to regulate the biological functions of the host.[] The high content of Akkermansia muciniphila is thought to play a major role in the health of the intestinal mucos, as well as regulate host immune responses and lipid metabolism. [] Many studies have noticed that a decrease of Akkermansia muciniphila in the mucus is tied with higher rates of obesity, increased inflammation, and an increase in Type 2 diabetes symptoms. []
Genome Structure
The complete genome of Akkermansia muciniphila has one circular chromosome of 2,664,102 bp with a G+C content of 55.8%.Akkermansia muciniphila has a total of 2,176 protein coding sequences and an overall coding capacity of 88.8%.[] Once sequenced, the genome was found to contain many candidate mucinase-encoding genes, but did not seem to have any genes for encoding canonical mucus-binding domains.[] Akkermansia muciniphila's genome did contain numerous phage-associated sequences, which indicates that viruses may have played a role in the evolution of the species.
Cell Structure, Metabolism and Life Cycle
Akkermansia muciniphila is able to use mucin as its sole source of carbon, nitrogen, and energy. It is an obligate chemo-organotroph, as found in a study that found no growth on a basal medium supplemented with vitamins and purged with H2/CO2. It was found that only a mucin medium was needed to culture A. muciniphila, as indicated in research that hypothesized that it survived solely on the mucin in the host intestine. Akkermansia muciniphila was found to produce acetate, propionate, and ethanol from mucin fermentation [].
Ecology and Pathogenesis
Habitat; symbiosis; biogeochemical significance; contributions to environment.
If relevant, how does this organism cause disease? Human, animal, plant hosts? Virulence factors, as well as patient symptoms.
Akkermansia muciniphila colonizes the mucosa layer of the host's gut, where it uses mucin as its sole source of carbon and nitrogen. [] Though many mucin degrading microbes in the intestinal layer of a host can be pathogenic, A. muciniphila has mostly positive associations with its host. Since A. muciniphila stays in the outer mucosal layer and does not reach the inner layer, any potential pathogenic behaviors are actually beneficial to the host because degrading mucin in the outer mucosal layer is considered a normal process in the intestinal self-renewal process. []
Many studies have found that Akkermansia muciniphila is linked to metabolic homeostasis and its presence in the intestine can help alleviate fat gain and type 2 diabetes as seen in experiments on mice and testing of human feces samples for A. muciniphila. Since A. muciniphila is located close to the animal host epithelial cells, it can exhibit significant regulatory responses. A study found that after exposure to A. muciniphila, the epithelial cell line activated TLR-2 expression and tight junction proteins, while reducing pro-inflammatory cytokines in the colon.[] This led to an increase in intestinal barrier integrity, and a decrease in inflammation which led to a decrease in obesity and type 2 diabetes symptoms.
Akkermansia muciniphila can also positively impact host response to cancer immunotherapy. A study found that consumption of antibiotics was associated with poorer response to immunotherapeutic PD-1 blockade. Fecal samples of cancer patients were tested to determine the levels of A. muciniphila present after antibiotic consumption and found that it was much lower in patients that had recently taken antibiotics, and that those patients also had a poorer response to the immunotherapy. Based on this research, it is suggested that maintaining a healthy gut flora, including mainly Akkermansia muciniphila is important to increase the effectiveness of cancer immunotherapy. []
References
Author
Page authored by Emma Schuster, student of Prof. Jay Lennon at IndianaUniversity.
